Compounds · Reproductive · Reproductive hormone regulation and fertility enhancement
Kisspeptin-10
KISS1(45-54), Metastin fragment 45-54, KP-10, KISS1 (112-121)
Potent vasoconstrictor and anti-angiogenic peptide best known as a key regulator of the hypothalamic-pituitary-gonadal axis, triggering GnRH release and downstream LH/FSH secretion. Studied for infertility, psychosexual disorders, and possible cancer applications.
0.1–0.2 mg, short courses
Research score 75/100. Reference only, not a prescription.
- Hormone Regulation
- Fertility Enhancement
- GnRH Agonist
- Libido Enhancement
- Reproductive Health
- US status
- Research Chemical
- Approval
- Phase 2 Clinical Trial
- Evidence
- Human studies for HSDD and fertility. Generally well-tolerated.
- Research score
- 75 / 100
- Indication
- Investigational - Reproductive Disorders
- Origin
- USA
- Source category
- Reproductive System
- Status group
- Research chemical
Mechanism
Binds the GPR54 (KISS1R) receptor on hypothalamic GnRH neurons, activating Gq/11 and phospholipase C signaling to raise calcium and drive pulsatile GnRH release, which prompts pituitary LH and FSH secretion and downstream gonadal hormone production.
Safety file
Favorable profile with no major side effects reported in human studies; short half-life limits prolonged adverse effects.
- Temporary hormone fluctuations
- Injection site reactions
- Headache
- Changes in menstrual cycle timing
Reconstitution
| Vial | 2 mL water | 3 mL water |
|---|---|---|
| 10 mg | 5 mg/mL | 3.33 mg/mL |
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
Protocol
Route: Subcutaneous
Community protocol (subcutaneous)
- A commonly used range is 0.1 mg to 0.2 mg (100 to 200 mcg) per dose, used in short courses rather than continuously
- Some run it alongside TRT support to nudge the natural hormone axis
Honest note on the data
- Most published human kisspeptin research uses intravenous infusions and the longer kisspeptin-54, not subcutaneous kisspeptin-10, so a precise injectable protocol is not well established
- Treat the above as a conservative community starting point and assess carefully
Dosing detail
- Community subcutaneous dosing is commonly 0.1 mg to 0.2 mg per dose, in short courses.
- Acts upstream on the hormone axis to stimulate LH and downstream testosterone.
- Strong human data is mostly from IV infusion studies, so injectable protocols are less settled than for, say, the GLP-1 drugs.
- Generally well tolerated in studies.
Duration
- Typically used in shorter cycles rather than continuously.
Notes
- Acts upstream on the hormone axis to stimulate LH and testosterone.
- Inject subcutaneously and rotate sites.
- Generally well tolerated.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.
NovaEvum vial
Worksheet
2 mL bacteriostatic water into 10 mg gives 5 mg/mL, 50 mcg/unit. A 100 mcg pulse is 2 units.
- Catalog fill
- 10 mg
- Typical water
- 2 mL
- Route
- Subcutaneous
- Cycle
- Short research blocks of 2–4 weeks.
| Step | Amount | Frequency | Notes |
|---|---|---|---|
| Common pulse | 100 mcg | Several times weekly | 2 units from a 2 mL reconstitution |
| Upper cited pulse | 200 mcg | Several times weekly | 4 units |
- This worksheet is not a fertility protocol and does not replace endocrine care.
- Bacteriostatic water: 20–25 °C. Do not refrigerate the diluent.
- Amounts on this sheet are reconstitution math for the vial, not a recommendation.